If you inject drugs, you likely already know that your risk for HIV is higher than average. What you may not know is that there is a highly effective, once-daily pill or a twice-yearly injection that can virtually eliminate that risk.

Despite the effectiveness of modern HIV prevention, a massive awareness gap exists. According to public health studies, only about 13% to 31% of people who inject drugs (PWID) have heard of PrEP (Pre-Exposure Prophylaxis). However, when educated about how it works, interest in starting PrEP jumps to over 60%.

At DevotedDOc, we provide the clinical “last mile” of care. We are a physician-led practice specializing in addiction medicine and infectious disease prevention. We believe that everyone—regardless of their history—deserves fast, expert, and judgment-free medical protection.

What This Means: Understanding PrEP and Your Risk

Pre-Exposure Prophylaxis (PrEP) is a medication taken by people who do not have HIV to prevent them from getting it. While much of the public conversation around PrEP focuses on sexual transmission, it is a critical tool for those who may share needles or injection equipment.

• How effective is it? When taken as prescribed, PrEP reduces the risk of getting HIV from sex by about 99%. For people who inject drugs, the CDC estimates that PrEP reduces the risk of HIV by at least 74% to 84%.
• The Interest Gap: Research published in Clinical Infectious Diseases and other peer-reviewed journals highlights a “perception gap.” Many PWID believe they are not at risk or simply haven’t been offered the medication by their doctors. Yet, once they learn about the protection PrEP offers, the majority of individuals are eager to start treatment.

What to Do Right Now: Step-by-Step Guidance

If you are worried about a recent exposure or want to start protecting yourself for the future, follow these steps immediately:

1. Check the 72-Hour Clock: If you shared a needle or had unprotected sex within the last 72 hours, you need PEP (Post-Exposure Prophylaxis), not PrEP. PEP is emergency medication that can stop an infection after it starts, but it must be initiated within three days of exposure.
2. Seek a “Status-Neutral” Consultation: This means talking to a doctor who doesn’t just “test” you but also provides a path forward. Whether you test negative and need PrEP or test positive and need rapid ART (Antiretroviral Therapy), the goal is the same: keeping you healthy.
3. Get a Same-Day Virtual Visit: You don’t need to wait for a specialty clinic appointment. Physician-led telehealth allows you to speak with a board-certified expert today from the privacy of your phone.
4. Secure Your Labs: You will need a baseline HIV test, as well as screens for kidney function and Hepatitis B/C, before starting prevention medication.

Testing and Timing: Understanding the Window Period

No HIV test can detect the virus immediately after exposure. Understanding the “window period” is essential for accuracy.

Test Type	Technology	Earliest Detection	Conclusive Result
NAT (Nucleic Acid Test)	Detects virus in blood	10 to 33 days	33 days
4th Gen Lab Test	Antigen + Antibodies	18 to 45 days	45 days
Rapid/Home Test	Antibodies only	23 to 90 days	90 days

Important: If you think you were exposed in the last 72 hours, do not wait for a test to turn positive. Start PEP immediately to prevent the virus from taking hold.

Modern Treatment Options for 2026

The clinical landscape for HIV and STI prevention has advanced significantly, offering more flexibility than ever before.

PEP (Emergency Prevention)

The 2025 CDC guidelines now recommend a preferred single-pill PEP regimen (Bictegravir/TAF/FTC). Taking one pill a day for 28 days is much easier and has fewer side effects than older multi-pill regimens.

PrEP (Ongoing Protection)

• Daily Pills: Tablets like Truvada or Descovy remain highly effective when taken every day.
• Yeztugo (Lenacapavir): Approved in 2025, this is a breakthrough twice-yearly injectable PrEP. After initial starter doses, you only need one injection every six months to maintain protection. This is an ideal option for those who struggle with “pill fatigue” or privacy.

Doxy PEP (STI Prevention)

If you are also concerned about syphilis or chlamydia, the CDC now recommends taking 200 mg of doxycycline within 72 hours after sex. This can reduce the risk of these STIs by over 70%.

Common Mistakes and Misconceptions

• “PrEP is only for certain groups.” Many PWID believe PrEP isn’t “for them.” In reality, anybody who may be exposed to HIV through shared equipment or sex is a candidate.
• “I’ll be judged if I ask for it.” Stigma from healthcare providers is a real barrier. Studies show that over 25% of primary care doctors are hesitant to prescribe PrEP to people who inject drugs. This is why specialized, physician-led telehealth is a safer, more discreet alternative.
• “I have to go to a physical clinic.” Telehealth has been proven as effective as in-person visits for HIV prevention, with higher retention rates in some studies because it removes the barriers of transportation and time away from work.

The DevotedDOc Solution: Physician-Led, Stigma-Free Care

DevotedDOc was built by board-certified Emergency and Addiction Physicians who saw too many patients fall through the cracks of the traditional healthcare system. We provide the “last mile” of care—the bridge from identifying a risk to starting effective treatment.

• Rapid Access: We treat PEP and HIV prevention as the medical emergencies they are. We offer same-day consultations to ensure you never miss a treatment window.
• Integrated Care: We understand that health is complex. We offer integrated services for HIV prevention, STI treatment, and addiction support (including Suboxone/MAT) in one seamless platform.
• Privacy & Dignity: Our visits are conducted virtually, allowing you to get expert care from the comfort of your home without the fear of being “outed” or judged at a local clinic.
• Clinical Authority: Unlike generic platforms, our protocols are designed by physicians for the best evidence-based outcomes. We coordinate your labs at a local facility and provide a clear, accountable follow-up plan.
  

Offer: Emergency STI/HIV Screening & Consultation

If you are worried about a recent exposure or ready to take control of your health with PrEP, we offer an Emergency Screening Protocol that includes:

• Same-Day Physician Consultation: Professional risk assessment and judgment-free counseling.
• Immediate Prescription Access: Rapid routing of PEP, PrEP, or Doxy PEP to your pharmacy.
• Coordinated Lab Testing: Orders for HIV, Hepatitis, and kidney function at a lab near you.
• Written Follow-Up Plan: A durable care roadmap to keep you negative and healthy.

Conclusion

The awareness gap for HIV prevention among people who inject drugs is a public health crisis, but it is one that can be solved. The tools to stay negative are more effective and convenient than ever before.

You don’t have to navigate this alone or face the judgment of a traditional waiting room. Take the first step toward peace of mind today. Connect with a DevotedDOc physician and get the expert protection you deserve.

References

1. Centers for Disease Control and Prevention (CDC). HIV Incidence, Diagnoses, and Care Outcomes: 2022. https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html 
2. CDC. Antiretroviral Postexposure Prophylaxis (PEP) Recommendations, 2025. https://www.cdc.gov/mmwr/indrr_2025.html 
3. National HIV/AIDS Strategy (NHAS). 2024 Progress Report: Ending the HIV Epidemic. https://files.hiv.gov/s3fs-public/2024-NHAS-Progress-Report.pdf 
4. Infectious Diseases Society of America (IDSA). 2024 Primary Care Guidance for Providers Who Care for Persons With HIV. https://www.idsociety.org/practice-guideline/primary-care-management-of-people-with-hiv/ 
5. U.S. Food and Drug Administration (FDA). Yeztugo® (lenacapavir) Prescribing Information, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220020s000lbl.pdf 
6. Journal of the American Medical Association (JAMA) Network Open. Telemedicine Preexposure Prophylaxis Prescribing Trends, 2025. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2842105 
7. World Health Organization (WHO). Consolidated Guidelines on HIV Prevention and Treatment, 2024-2025. https://www.who.int/publications/i/item/9789240031593 
8. American Psychological Association (APA). PrEP Access for People Who Inject Drugs. https://www.apa.org/topics/hiv-aids/prep-access-drug-users 
9. Journal of the International AIDS Society. Interest in PrEP among People Who Inject Drugs. https://jamanetwork.com/journals/jama/fullarticle/2827545